{"id":32462,"date":"2017-07-27T12:14:41","date_gmt":"2017-07-27T10:14:41","guid":{"rendered":"http:\/\/www.fedaiisf.it\/?p=32462"},"modified":"2017-07-27T12:14:41","modified_gmt":"2017-07-27T10:14:41","slug":"accordo-la-molmed-berlusconi-dompe-commercializzare-zalmoxis","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/accordo-la-molmed-berlusconi-dompe-commercializzare-zalmoxis\/","title":{"rendered":"Agreement between Berlusconi's Molmed and Domp\u00e8 to commercialize Zalmoxis"},"content":{"rendered":"

MolMed and Domp\u00e9 enter into an agreement for the marketing and supply of Zalmoxis<\/h1>\n

MolMed and Domp\u00e9 farmaceutici have entered into an exclusive licensing and distribution agreement for a period of 15 years. The agreement gives Domp\u00e9 the exclusive right and obligation to carry out all the activities aimed at promoting, marketing, enhancing, distributing and selling Zalmoxis in all member countries of the European Economic Area (EEA), with an option right for Switzerland, Turkey and Australia.<\/p>\n

\"Home\"\u201cBased on the terms and conditions of the license and distribution agreement, Domp\u00e9 will manage and\/or complete the market access activities and will take care of negotiating the redemption price of Zalmoxis in all the countries involved, with the exception of Italy \u201d.<\/p>\n

Simultaneously, MolMed and Domp\u00e9 have signed a production and supply agreement under which MolMed will be responsible for the production, supply and delivery of Zalmoxis to end users in the affected areas and Domp\u00e9 will pay a purchase price proportional to the reimbursement price of the product.<\/p>\n

In addition to the purchase price, the licensing and distribution agreement guarantees MolMed to receive up to 43.5 million euros, of which up to 12.5 million as a contribution in the period 2017-2020, and up to 31 million under form of milestones recognized upon the achievement of certain levels of annual net sales collected in the territory covered by the contract.<\/p>\n

The MLM share on the Piazza Affari price list rose by 4.66% to 0.44 euro.<\/p>\n

FOL Finance online \u2013\u00a0

QUOTES\u00a0Molmed<\/a><\/p>\n

Related news:\u00a0Molmed, or the other 'M' of Fininvest that shakes Berlusconi's sleep<\/a><\/span><\/p>\n

Berlusconi animal rights activist, but finances animal experimentation<\/span><\/a><\/p>\n

MolMed Shareholders<\/h3>\n

Social capital<\/strong>\u00a0\u00a0: \u20ac 20,312,682.30 fully subscribed and paid<\/p>\n

Total shares outstanding<\/strong>\u00a0: 431,450,672 (ordinary shares at 100% without par value)<\/p>\n

Shareholders<\/strong>\u00a0\u2013 based on the data available to the Company as at 7 November 2016:<\/p>\n\n\n\n\n\n\n\n\n\n
Shareholder<\/span><\/th>\nNo shares<\/span><\/th>\n%<\/span><\/th>\n<\/tr>\n<\/thead>\n
Fininvest SpA<\/td>\n107.173.138<\/td>\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 24.84<\/td>\n<\/tr>\n
Airain Ltd.<\/td>\n24.037.678 (*)<\/td>\n5.57<\/td>\n<\/tr>\n
H-Invest SpA<\/td>\n11.512.216<\/td>\n2.67<\/td>\n<\/tr>\n
H Equity Srl<\/td>\n8.579.208<\/td>\n1.99<\/td>\n<\/tr>\n
Others <5%<\/td>\n280.148.432<\/td>\n64.93<\/td>\n<\/tr>\n<\/tbody>\n<\/table>","protected":false},"excerpt":{"rendered":"

MolMed e Domp\u00e9 stipulano un accordo per commercializzazione e fornitura di Zalmoxis MolMed e Domp\u00e9 farmaceutici hanno stipulato un accordo esclusivo di licenza e distribuzione della durata di 15 anni. Il contratto attribuisce in via esclusiva a Domp\u00e9 il diritto e l\u2019obbligo di svolgere tutte le attivit\u00e0 indirizzate a promuovere, commercializzare, valorizzare, distribuire e vendere …<\/p>","protected":false},"author":4,"featured_media":32464,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[53],"class_list":["post-32462","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-fusioniacquisizioni"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/32462","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=32462"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/32462\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/32464"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=32462"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=32462"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=32462"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}